🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Administration of ceralasertib monotherapy

Found 10 matching trials

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

PHASE1

This biomarker study has been designed to assess the effects of different a...

Status

Completed

Location

Research Site

Start Date

2017-09-18

Trial ID

NCT03022409

Treatments Being Tested

Ceralasertib Olaparib

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

PHASE2

This phase II trial studies how well ceralasertib, am Ataxia telangiectasia...

Status

Active Not Recruiting

Location

City of Hope Comprehensive Cancer Center

Start Date

2019-01-17

Trial ID

NCT03682289

Treatments Being Tested

Ceralasertib Olaparib Durvalumab

AMTEC IIT: Phase 2 Multiarm Study in TNBC

PHASE2

This phase II study assesses the efficacy of the combination of olaparib wi...

Status

Terminated

Location

OHSU Knight Cancer Institute

Start Date

2018-12-12

Trial ID

NCT03801369

Treatments Being Tested

Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life Assessment Selumetinib

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

PHASE1

This is a modular, phase I/ phase 1 b, open-label, multicentre study of cer...

Status

Active Not Recruiting

Location

Research Site

Start Date

2014-10-31

Trial ID

NCT02264678

Treatments Being Tested

Administration of ceralasertib Administration of ceralasertib in combination with olaparib Administation of ceralasertib in combination with durvalumab Administration of ceralasertib monotherapy Administration of ceralasertib and olaparib Administration of ceralasertib and durvalumab Administration of ceralasertib in combination with AZD5305 Administration of ceralasertib in combination with carboplatin

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

PHASE2

This study is to assess the efficacy and safety of olaparib monotherapy ver...

Status

Active Not Recruiting

Location

Research Site

Start Date

2018-03-07

Trial ID

NCT03330847

Treatments Being Tested

Olaparib Continuous (28-Day cycle) 300 mg BD.Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

PHASE2

PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase I...

Status

Recruiting

Location

Royal Bournemouth Hospital

Start Date

2019-10-15

Trial ID

NCT03740893

Treatments Being Tested

AZD6738 Olaparib Durvalumab

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

PHASE2

To investigate the effectiveness and tolerability of a second maintenance t...

Status

Withdrawn

Location

Research Site

Start Date

2020-08-07

Trial ID

NCT04239014

Treatments Being Tested

Olaparib Ceralasertib Placebo to match olaparib

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

PHASE1

This is a Phase 1, open-label study designed to evaluate the safety, tolera...

Status

Completed

Location

Research Site

Start Date

2022-06-09

Trial ID

NCT05469919

Treatments Being Tested

Ceralasertib

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

PHASE2

Study design This is a Phase II, open-label, multi-drug, multi-center, mult...

Status

Completed

Location

Research Site

Start Date

2016-11-28

Trial ID

NCT02937818

Treatments Being Tested

Durvalumab and Tremelimumab AZD1775 and carboplatin (CBPT)AZD6738 and olaparib

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

PHASE2

Main study: This is an open-label, phase 2 study that aims to evaluate the ...

Status

Active Not Recruiting

Location

Research Site

Start Date

2022-08-11

Trial ID

NCT05061134

Treatments Being Tested

Ceralasertib Durvalumab

Previous Next